Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) issued its quarterly earnings data on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by $0.36, StockRatingsNetwork reports. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the previous year, the company posted $1.78 earnings per share. The company’s revenue for the quarter was up 42.3% on a year-over-year basis.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.94% on Thursday, hitting $281.10. The stock had a trading volume of 180,746 shares. Regeneron Pharmaceuticals has a 52-week low of $206.30 and a 52-week high of $352.49. The stock has a 50-day moving average of $299. and a 200-day moving average of $296.9. The company has a market cap of $27.871 billion and a P/E ratio of 75.24.

REGN has been the subject of a number of recent research reports. Analysts at UBS AG reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. They now have a $320.00 price target on the stock, up previously from $310.00. On a related note, analysts at Robert W. Baird raised their price target on shares of Regeneron Pharmaceuticals from $362.00 to $368.00 in a research note on Monday. Finally, analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 30th. They now have a $359.00 price target on the stock. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $345.40.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.